Repligen (NASDAQ:RGEN) Shares Down 4.8% – Should You Sell?

Repligen Co. (NASDAQ:RGEN) shares traded down 4.8% during trading on Friday . The stock traded as low as $133.33 and last traded at $135.54. 23,261 shares changed hands during trading, a decline of 96% from the average session volume of 657,365 shares. The stock had previously closed at $142.43.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on RGEN shares. Wolfe Research assumed coverage on Repligen in a report on Thursday. They issued a “peer perform” rating on the stock. Stephens reaffirmed an “overweight” rating and issued a $170.00 price objective on shares of Repligen in a research note on Tuesday, July 30th. StockNews.com upgraded Repligen from a “sell” rating to a “hold” rating in a research report on Wednesday. JPMorgan Chase & Co. boosted their price target on shares of Repligen from $190.00 to $200.00 and gave the stock an “overweight” rating in a research report on Wednesday, July 31st. Finally, Wells Fargo & Company assumed coverage on shares of Repligen in a research report on Tuesday, August 27th. They set an “overweight” rating and a $180.00 price objective for the company. Four research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $190.25.

Repligen Price Performance

The stock has a 50 day moving average of $141.59 and a 200-day moving average of $144.78. The company has a current ratio of 6.65, a quick ratio of 5.56 and a debt-to-equity ratio of 0.26. The stock has a market capitalization of $7.07 billion, a P/E ratio of -361.50, a price-to-earnings-growth ratio of 4.36 and a beta of 0.96.

Repligen (NASDAQ:RGEN) last issued its earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.34 by $0.09. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.92%. The firm had revenue of $154.87 million during the quarter, compared to analyst estimates of $153.34 million. During the same period in the previous year, the firm earned $0.23 earnings per share. The business’s revenue was up 9.7% on a year-over-year basis. On average, equities research analysts anticipate that Repligen Co. will post 1.44 earnings per share for the current fiscal year.

Insider Activity at Repligen

In related news, Director Anthony Hunt sold 22,191 shares of the company’s stock in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $145.37, for a total value of $3,225,905.67. Following the completion of the sale, the director now directly owns 139,840 shares of the company’s stock, valued at $20,328,540.80. This represents a 13.70 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 1.20% of the stock is owned by company insiders.

Institutional Investors Weigh In On Repligen

Several large investors have recently modified their holdings of the business. Andra AP fonden bought a new position in Repligen in the second quarter worth approximately $25,000. International Assets Investment Management LLC bought a new position in shares of Repligen in the 2nd quarter worth $33,000. UMB Bank n.a. lifted its stake in shares of Repligen by 138.3% during the 3rd quarter. UMB Bank n.a. now owns 224 shares of the biotechnology company’s stock worth $33,000 after purchasing an additional 130 shares during the last quarter. Lazard Asset Management LLC boosted its position in Repligen by 206.1% during the first quarter. Lazard Asset Management LLC now owns 202 shares of the biotechnology company’s stock valued at $36,000 after purchasing an additional 136 shares in the last quarter. Finally, Blue Trust Inc. grew its stake in Repligen by 113.4% in the third quarter. Blue Trust Inc. now owns 239 shares of the biotechnology company’s stock valued at $36,000 after purchasing an additional 127 shares during the last quarter. Institutional investors own 97.64% of the company’s stock.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.